Cargando…
Correction: Davidi et al. Tumor Treating Fields (TTFields) Concomitant with Sorafenib Inhibit Hepatocellular Carcinoma In Vitro and In Vivo. Cancers 2022, 14, 2959
Autores principales: | Davidi, Shiri, Jacobovitch, Sara, Shteingauz, Anna, Martinez-Conde, Antonia, Braten, Ori, Tempel-Brami, Catherine, Zeevi, Einav, Frechtel-Gerzi, Roni, Ene, Hila, Dor-On, Eyal, Voloshin, Tali, Tzchori, Itai, Haber, Adi, Giladi, Moshe, Kinzel, Adrian, Weinberg, Uri, Palti, Yoram |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9954138/ https://www.ncbi.nlm.nih.gov/pubmed/36831698 http://dx.doi.org/10.3390/cancers15041182 |
Ejemplares similares
-
Tumor Treating Fields (TTFields) Concomitant with Sorafenib Inhibit Hepatocellular Carcinoma In Vitro and In Vivo
por: Davidi, Shiri, et al.
Publicado: (2022) -
Tumor-treating fields (TTFields) induce immunogenic cell death resulting in enhanced antitumor efficacy when combined with anti-PD-1 therapy
por: Voloshin, Tali, et al.
Publicado: (2020) -
In Vivo Safety of Tumor Treating Fields (TTFields) Applied to the Torso
por: Blatt, Roni, et al.
Publicado: (2021) -
AMPK-dependent autophagy upregulation serves as a survival mechanism in response to Tumor Treating Fields (TTFields)
por: Shteingauz, Anna, et al.
Publicado: (2018) -
Determining the Optimal Inhibitory Frequency for Cancerous Cells Using Tumor Treating Fields (TTFields)
por: Porat, Yaara, et al.
Publicado: (2017)